Inactive Instrument

News Repros Therapeutics Inc

Stocks

US76028H2094

Biotechnology & Medical Research

All News

18-01-26	Repros Announces Negative Opinion From the EMA for Enclomiphene	GL
17-12-15	Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency	GL
17-12-12	REPROS THERAPEUTICS INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout	BU
17-12-12	Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Repros Therapeutics Inc. to Allergan plc is Fair to Shareholders	BU
17-12-12	Repros Therapeutics Inc.® Announces Acquisition by Allergan plc	GL
17-11-13	Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results	GL
17-08-14	Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results	GL
17-07-17	Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA	GL
17-05-18	Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock	GL
17-05-17	Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock	GL
17-05-09	Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results	GL
17-04-17	Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions	GL
17-04-10	Repros Names Larry Dillaha, M.D., its Permanent President and CEO	GL
17-04-10	Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids	GL
17-03-31	Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results	GL
17-02-02	Repros Announces New CEO	GL
17-01-30	FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids	GL
16-12-19	Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis	GL
16-12-12	Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids	GL
16-12-06	FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism	GL
16-11-14	Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered Orally and Vaginally for the Treatment of Uterine Fibroids	GL
16-11-08	Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results	GL
16-10-05	Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities	GL
16-09-26	FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism	GL
16-09-12	Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism	GL